Podcasts

Episode 23 | Cardiotoxicity and Radiation Therapy - Considerations for Lung Cancer

Cardiotoxicity and Radiation Therapy - Considerations for Lung Cancer

Episode Summary

For lung cancer patients, the benefits of treatment and potential for cure must always be balanced with risk. Cardiotoxicity is considered a short and long term risk from treatment for lung cancer, but this varies between patients. New radiotherapy techniques, lower doses of radiotherapy and supporting cardiovascular treatments can minimise the risk of cardiotoxicity. Monitoring for cardiac complications is becoming an important aspect of survivorship care, and may require collaboration between medical oncologists, radiation oncologists, GPs and cardiologists. Prof Shalini Vinod discusses the challenges with Dr Vicky Chin and Dr James Otton. 

Show Hosts

This episode’s host are:

  • Prof Shalini Vinod, Communications and Grants Chair, TOGA; Radiation Oncologist, Liverpool Hospital; Conjoint Professor University of New South Wales; Honorary Professor, University of Wollongong
  • Dr Vicky Chin, Radiation Oncologist, University of New South Wales
  • A/Prof James Otton, Cardiologist, Liverpool Hospital

Play Episode 23 | Cardiotoxicity and Radiation Therapy - Considerations for Lung Cancer

More Podcasts

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and
In this introductory episode, A/Prof Mel Moore, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.'
Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC
Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.
A/Prof Rachel Wong is joined by Dr Patrick Hosking, Dr Mal Itchins, and Dr Sagun Parakh discuss the diagnostic markers when identifying LC-NEC.
We dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining